US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma

OBJECTIVE: To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with penta-refractory multiple myeloma (MM) from the perspective of a third-party payer in the United States (US). METHODS: A budget impact analysis was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassali, Jan, Gould, Ian Gopal, Kaye, James A, Mladsi, Deirdre, Mehta, Jyotsna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310980/
https://www.ncbi.nlm.nih.gov/pubmed/32606848
http://dx.doi.org/10.2147/CEOR.S251070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310980/
https://www.ncbi.nlm.nih.gov/pubmed/32606848
http://dx.doi.org/10.2147/CEOR.S251070

Ejemplares similares